iX Biopharma has been granted a patent in Israel for its WaferiX drug delivery technology. The patent will expire on October 11, 2033, and will provide key intellectual property protection for the company's WaferiX delivery technology platform in Israel.
The company has also received a patent from the United States Patent and Trademark Office (USPTO), which will expire on October 26, 2030.
iX Biopharma says its intellectual property rights for its sublingual wafer technology is now secured in five continents and all key markets including the US, China, Australia, New Zealand, Singapore, Malaysia, Japan, and South Korea.
Shares in iX Biopharma closed flat at 22 cents on September 18.
